Eli Lilly’s Oncology Unit Gets US FDA Approval from Jayprica to Treat Mantle Cell Lymphoma
Loxo@Lilly, Eli Lilly and Company’s oncology division, has received US FDA approval for Jaypirca (pirtobrutinib, 100 mg and 50 mg tablets) to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Based on the response rate from the […]
Continue Reading